AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01474395 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-serine
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Study NCT01474395 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
Study NCT01474395 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sensory Based remediation paradigm
Description: Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
Study NCT01474395 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Sensory Based remediation paradigm
Description: Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (\~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
Study NCT04273321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone 1mg/kg/day ivgtt for 7 days.
Study NCT02221752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous Sulfate + folic acid
Description: Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate \[60 mg elemental iron\]) and the other with 0.40 mg folic acid from enrollment to delivery.
Study NCT02221752 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic acid
Description: Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
Study NCT01645436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise training
Description: The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
Study NCT04718597 — intervention group
Intervention type: PROCEDURE
Intervention: Robotic assisted inguinal hernia repair
Description: Robotic assisted inguinal hernia repair with DaVinci Xi system instead of open repair
Study NCT04718597 — intervention group
Intervention type: PROCEDURE
Intervention: Open inguinal hernia repair
Description: Classical approach (open repair)
Study NCT05190796 — intervention group
Intervention type: OTHER
Intervention: platelet indices
Description: One sample of 20 mL venous blood was drawn by standard phlebotomy from all of the participants. This sample was kept for the evaluation of hemoglobin, hematocrit, mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), red cell distribution width (RDW), erythrocyte count, leukocyte count, platelet count, platelet distribution width (PDW), MPV and plateletcrit by means of an automated commercial counter (Coulter counter, Max Instruments Laboratory). After this venous blood sample was conveyed into a sodium citrate tube, it was transported in a temperature-controlled container and collected in plastic provettes (Falcon blue cap) containing 3 mL of 3.8% sodium citrate dihydrate and 136 mM glucosium. Then the samples were sent to the laboratory.
Study NCT00039403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine
Description: Given IV
Study NCT00039403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV
Study NCT00039403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT00039403 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03271138 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium infantis NLS super strain (Natren LIFE START®2)
Description: 2 capsules, 3 times per day, for daily total of 12x10\^9 CFU Bifidobacterium infantis NLS super strain
Study NCT03271138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
Study NCT05200169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14C-AB1010
Description: Oral solution of 14C radiolabelled AB1010 (200 mg per subject)
Study NCT02273401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 11054 CL
Study NCT02273401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01376869 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hops Extract
Description: All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
Study NCT01376869 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (silica)
Description: All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
Study NCT03107429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide tablets were placed in capsules to make them look similar to placebo.
Study NCT03107429 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo was a sugar based placebo placed in a capsule.
Study NCT03107429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trendelenburg Position
Description: Placed in Trendelenburg Position
Study NCT03107429 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Trendelenburg Position
Description: Placed in Trendelenburg Position
Study NCT03735290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ilixadencel
Description: Intra-tumoral injection
Study NCT02249598 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02807818 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home visiting Program for Young Pregnant Women
Study NCT02285153 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid lysinate
Description: 100mg intravenously administered Acetylsalicylic Acid lysinate per day
Study NCT03735290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
Study NCT03735290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pembrolizumab
Description: Administered intravenously over 30 minutes, every 3 weeks, at a dose of 200 mg
Study NCT02022358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucarpidase
Description: Glucarpidase rescue (50 units/kg x 1, intravenously)
Study NCT02022358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate (12 g/m2 x 1, intravenously)
Study NCT02022358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate (12 g/m2 x 1, intravenously)
Study NCT02022358 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Folinic Acid
Description: Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
Study NCT02022358 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folinic Acid
Description: Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
Study NCT01003106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.5mg (monthly)
Description: Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
Study NCT01003106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 2.0mg (monthly)
Study NCT01003106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pro re nata (prn) ranibizumab
Study NCT01003106 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pro re nata (prn) Laser photocoagulation
Study NCT02860988 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MCCC treatment
Description: Participants in this condition received newly-supported reentry services to enhance fatherhood and parenting for individuals with substance use issues. These services focus on responsible parenting, economic stability and mobility, and healthy marriage and relationships.
Study NCT01530542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: oxycodone hydrochloride 5 mg tablet under fasted conditions
Study NCT01530542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: 2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
Study NCT01530542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
Study NCT01530542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone hydrochloride
Description: 2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
Study NCT01530542 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: marketed oxycodone hydrochloride
Description: 1 x oxycodone hydrochloride 15 mg tablet under fed conditions
Study NCT01953029 — intervention group
Intervention type: PROCEDURE
Intervention: cardiac imajing
Description: Cardiac MRI
Study NCT01825824 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic ablative radiotherapy
Description: The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
Study NCT00461058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Actos
Description: Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
Study NCT00461058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aleglitazar
Description: Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
Study NCT04514900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Chat +Personalized Feedback
Description: Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide detailed weekly feedback on diet and exercise.
Study NCT04514900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Chat + Basic Feedback
Description: Participants will receive an online 16-session, goal-driven behavioral weight control program via video chat and weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A group facilitator will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
Study NCT04514900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion Board for Social Support +Basic Feedback
Description: Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide basic weekly feedback on diet and exercise.
Study NCT04514900 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion Board for Social Support+Personalized Feedback
Description: Participants will receive an online 16-session, goal-driven behavioral weight control program via weekly interactive modules. The modules provide evidence-based health education on caloric balance, with a goal of fostering changes in diet and exercise habits and producing weight losses of 5-10%. They also are provided with a study discussion board for social support from fellow participants. Participants are provided with an electronic scale that will transmit weights wirelessly to a secure study website. A weight loss counselor will monitor digital food diaries and provide personalized, detailed weekly feedback on diet and exercise.
Study NCT02687854 — intervention group
Intervention type: DRUG
Intervention: Apixaban
Description: As prescribed by treating physicians
Study NCT02687854 — intervention group
Intervention type: DRUG
Intervention: Vitamin K antagonist
Description: As prescribed by treating physicians
Study NCT00664586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terameprocol (EM-1421)
Description: Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
Study NCT02285153 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% sodium-chloride solution
Description: Placebo, intravenously administered, daily
Study NCT01284868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mirabegron
Description: oral
Study NCT01284868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Description: oral
Study NCT02055391 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral Weight Loss
Description: Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
Study NCT02055391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Weight Loss
Description: Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
Study NCT02549456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: natural orifice specimen extraction
Description: Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
Study NCT01284868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: propranolol
Description: oral
Study NCT02549456 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoendoscopic resection
Description: Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.~Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed.
Study NCT01284868 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral
Study NCT01217593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
Study NCT01217593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: predetermined distance
Description: The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
Study NCT00553774 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cocoa Flavanols
Description: Cocoa Flavanols (BD for 21 - 28 days)
Study NCT00553774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (BD 21 - 28 Days)
Study NCT01123330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Study NCT01123330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Study NCT04044118 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Calorie Diet
Description: Low Calorie Diet consisted of \~50% calories of a normal-calorie diet (female, 1000kcal/day; male, 1200kcal/day)
Study NCT04227912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Transversus abdominis plane block
Description: Before surgery, Ultrasound-guided TAP block was performed preemptively to Group TAP patients.
Study NCT04227912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthetic infiltration
Description: Before surgery, Ultrasound-guided Local anesthetic infiltration to the surgical incision line was performed preemptively to Group Local patients.
Study NCT04227912 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous dexketoprofen
Description: Before surgery, 50 mg intravenous dexketoprofen was performed preemptively to Group dexketoprofen patients.
Study NCT00818935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low-Intermediate-Glycemic Index diets
Study NCT00818935 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High GI diet
Study NCT01878799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GS-7977/GS- 5885 FDC
Description: The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
Study NCT03499795 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VGX-3100
Description: One milliliter (1 mL) VGX-3100 (deoxyribonucleic acid \[DNA\] plasmids encoding E6 and E7 proteins of HPV types 16 and 18) will be injected IM and delivered by EP using CELLECTRA™ 5PSP on Day 0, Week 4 and Week 12, and potentially Week 40.
Study NCT03499795 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™ 5PSP
Description: IM injection of VGX-3100 is followed by EP with the CELLECTRA™ 5PSP device.
Study NCT00183339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Description: Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.